|1.||Adín, Javier: 1 article (04/2005)|
|2.||Vega-Gil, Noelia: 1 article (04/2005)|
|3.||Herranz, José L: 1 article (04/2005)|
|4.||Shushtarian, Mehrdad: 1 article (04/2005)|
|5.||Armijo, Juan A: 1 article (04/2005)|
|6.||Christensen, J: 1 article (08/2001)|
|7.||Balslev, T: 1 article (08/2001)|
|8.||Poulsen, J H: 1 article (08/2001)|
|9.||Dam, M: 1 article (08/2001)|
|10.||Villadsen, J: 1 article (08/2001)|
|1.||Trigeminal Neuralgia (Tic Douloureux)
01/01/1990 - "Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia."
01/01/1987 - "The dihydroketo and dihydromonohydroxy analogues of carbamazepine (GP 47680 and GP 47779) were tested against carbamazepine for efficacy and tolerability in 13 patients (6 male and 7 female, mean age 69 years) and 11 patients (5 male and 6 female, mean age 64 years), respectively, all of whom were suffering from trigeminal neuralgia. "
12/27/1994 - "Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures."
01/01/1989 - "The criteria for assessment were: efficacy--seizure frequency, EEG tracings, global evaluation; tolerability--side effects observed by the patient or the investigator, laboratory tests; other assessments--blood pressure and heart rate, carbamazepine and 10,11-dihydro-10-hydroxycarbamazepine trough serum levels. "
|3.||Body Weight (Weight, Body)
04/01/2005 - "The influence of patient age and concomitant AEDs on the trough steady-state serum concentration of 10-hydroxycarbazepine (OHC) normalized to 1 mg/kg body weight of OXC or concentration-to-dose ratio (OHC-OXC-CDR) was assessed by analysis of covariance. "
04/01/1989 - "An overall serum therapeutic concentration range, in the six patients, of 50-110 mumol/l of 10-OH-carbazepine corresponding to a daily effective dose range of 1200-2400 mg (14.6-35.6 mg/kg body weight) oxcarbazepine, was observed. "
|5.||Muscle Spasticity (Spastic)
|4.||Carrier Proteins (Binding Protein)